Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.92 USD | -1.68% | -4.89% | -10.57% |
Apr. 24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
Apr. 08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Business Summary
Number of employees: 31
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia, Switzerland and Spain
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Chief Tech/Sci/R&D Officer | - | 19-02-28 | |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Comptroller/Controller/Auditor | 35 | 22-06-30 | |
Corporate Officer/Principal | - | - | |
Manolo Bellotto
PRN | Corporate Officer/Principal | 53 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 20-12-31 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 20-12-31 |
Director/Board Member | 68 | 20-12-31 | |
Jeffrey Riley
BRD | Director/Board Member | 61 | 19-04-30 |
Khalid Islam
FOU | Founder | 67 | 16-12-31 |
Claude Nicaise
BRD | Director/Board Member | 71 | 20-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,051,979 | 15,383,745 ( 85.22 %) | 0 | 85.22 % |
Company contact information
Gain Therapeutics, Inc.
4800 Montgomery Lane Suite 220
20814, Bethesda
+
http://www.gaintherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.12% | 53.61M | |
+24.93% | 42.68B | |
-3.14% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.22% | 24.94B | |
-20.16% | 18.96B | |
+28.88% | 12.3B | |
-2.82% | 11.95B | |
-1.52% | 11.55B |
- Stock Market
- Equities
- GANX Stock
- Company Gain Therapeutics, Inc.